이중특이성항체 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 적응증별, 지역별, 경쟁별(2020-2030년)
Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), By Region & Competition, 2020-2030F
상품코드:1668079
리서치사:TechSci Research
발행일:2025년 02월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
이중특이성항체 세계 시장 규모는 2024년 68억 달러로 평가되며 예측 기간 동안 2030년까지 연평균 9.40%의 괄목할 만한 성장을 보일 것으로 예상됩니다.
세계 이중특이성항체 시장은 바이오의약품 산업의 큰 성장과 혁신을 목격하고 있습니다. 이중특이성항체는 두 개의 서로 다른 항원을 동시에 표적으로 삼도록 설계된 치료용 단백질의 일종으로, 암과 자가면역질환 등 다양한 질병을 치료할 수 있는 독창적인 접근법을 제공합니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
68억 달러
시장 규모 : 2030년
116억 8,000만 달러
CAGR : 2025-2030년
9.40%
급성장 부문
암
최대 시장
북미
시장 촉진요인
암과 자가면역질환의 유병률 상승
주요 시장 과제
복잡한 설계 및 제조
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 이중특이성항체 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
적응증별(암, 염증성 질환 및 자가면역질환, 기타)
지역별
기업별(2024년)
제품 시장 맵
적응증별
지역별
제6장 북미의 이중특이성항체 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
캐나다
멕시코
제7장 유럽의 이중특이성항체 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
영국
프랑스
이탈리아
스페인
제8장 아시아태평양의 이중특이성항체 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
일본
인도
호주
한국
제9장 남미의 이중특이성항체 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 이중특이성항체 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
쿠웨이트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
인수합병
제품 출시
제13장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제14장 경쟁 구도
Amgen Inc
F. Hoffmann-La Roche Ltd
Genentech Inc
Akeso Inc
Janssen(Johnson & Johnson Private Limited)
Taisho Pharmaceutical Co Ltd
Immunocore Ltd
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
Global Bispecific Antibodies Market was valued at USD 6.80 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.40% through 2030. The global bispecific antibodies market has been witnessing significant growth and innovation in the biopharmaceutical industry. Bispecific antibodies are a class of therapeutic proteins designed to simultaneously target two different antigens, providing a unique approach to treating various diseases, including cancer and autoimmune disorders.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 6.80 Billion
Market Size 2030
USD 11.68 Billion
CAGR 2025-2030
9.40%
Fastest Growing Segment
Cancer
Largest Market
North America
Key Market Drivers
Rising Prevalence of Cancer and Autoimmune Diseases
The global bispecific antibodies (BsAbs) market is experiencing rapid expansion, primarily driven by the increasing incidence of cancer and autoimmune diseases worldwide. This trend is significantly boosting the demand for innovative, targeted biologics, positioning bispecific antibodies as a key therapeutic solution. In 2022, global cancer statistics revealed significant healthcare and economic challenges, with approximately 20 million new cancer cases diagnosed and 9.7 million cancer-related deaths recorded worldwide. The prevalence of cancer survivors within five years of diagnosis reached 53.5 million, underscoring the growing burden on healthcare systems to provide long-term care and support. Epidemiological data indicates that 1 in 5 individuals will develop cancer during their lifetime, with gender-specific mortality rates highlighting a higher risk among men (1 in 9) compared to women (1 in 12). These figures emphasize the critical need for innovative therapeutic solutions, early detection strategies, and scalable treatment options to address the rising global cancer burden. This rise is attributed to aging populations, lifestyle changes, and environmental factors. The growing cancer burden is increasing demand for advanced, highly effective therapies, which is propelling the adoption of bispecific antibodies in oncology. Unlike traditional monoclonal antibodies (mAbs), bispecific antibodies can simultaneously bind to two different antigens, enhancing tumor cell killing while reducing immune evasion. BsAbs can recruit and activate T cells or NK cells to attack tumor cells, offering a powerful alternative to standard chemotherapy and single-target biologics. Many cancer therapies face resistance over time, but BsAbs help overcome resistance mechanisms by targeting multiple pathways. BsAbs provide a more accessible and cost-effective option compared to personalized CAR-T therapies, which require complex manufacturing processes.
Key Market Challenges
Complex Design and Manufacturing
One of the primary challenges in the bispecific antibodies market is the complexity of their design and manufacturing processes. Creating bispecific antibodies that can simultaneously bind to two distinct molecules or cells requires precise engineering. The intricacies of their structure can lead to manufacturing challenges, impacting scalability, production costs, and consistency in quality.
Key Market Players
Amgen Inc
F. Hoffmann-La Roche Ltd
Genentech Inc
Akeso Inc
Janssen (Johnson & Johnson Private Limited)
Taisho Pharmaceutical Co Ltd
Immunocore Ltd
Report Scope:
In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Bispecific Antibodies Market, By Indication:
Cancer
Inflammatory & Autoimmune Disorders
Others
Bispecific Antibodies Market, By Region:
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Asia-Pacific
China
Japan
India
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.
Available Customizations:
Global Bispecific Antibodies market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Bispecific Antibodies Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
5.2.2. By Region
5.2.3. By Company (2024)
5.3. Product Market Map
5.3.1. By Indication
5.3.2. By Region
6. North America Bispecific Antibodies Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
6.2.2. By Country
6.3. North America: Country Analysis
6.3.1. United States Bispecific Antibodies Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.2. Canada Bispecific Antibodies Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.3. Mexico Bispecific Antibodies Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
7. Europe Bispecific Antibodies Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
7.2.2. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Bispecific Antibodies Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.2. United Kingdom Bispecific Antibodies Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.3. France Bispecific Antibodies Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.4. Italy Bispecific Antibodies Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.5. Spain Bispecific Antibodies Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
8. Asia-Pacific Bispecific Antibodies Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
8.2.2. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Bispecific Antibodies Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.2. Japan Bispecific Antibodies Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.3. India Bispecific Antibodies Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.4. Australia Bispecific Antibodies Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.5. South Korea Bispecific Antibodies Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
9. South America Bispecific Antibodies Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
9.2.2. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Bispecific Antibodies Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.2. Argentina Bispecific Antibodies Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.3. Colombia Bispecific Antibodies Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
10. Middle East and Africa Bispecific Antibodies Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
10.2.2. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Bispecific Antibodies Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.2. Saudi Arabia Bispecific Antibodies Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.3. UAE Bispecific Antibodies Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.4. Kuwait Bispecific Antibodies Market Outlook
